NCT04592913: Phase 3: (MATTERHORN): Neoadjuvant FLOT +/- Durvalumab Followed by Adjuvant FLOT +/- Durvalumab in GC/GEJC

First Posted	2020-10-19
Trial status	Active, not recruiting
Sponsor	AstraZeneca
Abstract Presentation	Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). Meeting Abstract: 2025 ASCO Annual Meeting II Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary June 04, 2025 Click here for details
Peer-reviewed journal publication	NEJM: Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer N Engl J Med. 2025 Jul 17 PUBMED NEJM MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer Future Oncol. 2022 Jun;18 PUBMED
FDA	FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma November 25, 2025 Click here for details
Press Release	Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers November 25, 2025 Click here for details
NCCN	GAS125 ESO128

NCT04592913: Phase 3: (MATTERHORN): Neoadjuvant FLOT +/- Durvalumab Followed by Adjuvant FLOT +/- Durvalumab in GC/GEJC

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Official Title:

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

Intervention / Treatment:

Drug: Durvalumab

Drug: FLOT chemotherapy

Other Study ID Numbers:

D910GC00001

2019-001555-40 ( EudraCT Number )

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT04592913